Searle regulatory update

The FDA granted marketing approval for Searle's Celebrex celecoxib, a COX-2 inhibitor to treat osteoarthritis (OA) and rheumatoid arthritis (RA). Searle and partner Pfizer Inc. (New York, N.Y.) wil...